[{"orgOrder":0,"company":"Ascletis Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"ASC41","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Ascletis Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Ascletis Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Ascletis Pharma \/ Not Applicable"},{"orgOrder":0,"company":"RespireRx Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2021","type":"Not Applicable","leadProduct":"ERX-1000","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"RespireRx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Oral pill","sponsorNew":"RespireRx Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"RespireRx Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2021","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC3\/4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Janssen Sciences Ireland Unlimited","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2021","type":"Licensing Agreement","leadProduct":"CIN-109","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Janssen Sciences Ireland Unlimited"},{"orgOrder":0,"company":"Gmax Biopharm","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"GMA106","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gmax Biopharm","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gmax Biopharm \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gmax Biopharm \/ Not Applicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Ecnoglutide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"MC4 receptor","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Sciwind Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2022","type":"Not Applicable","leadProduct":"XW014","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sciwind Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Sciwind Biosciences \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sciwind Biosciences \/ Not Applicable"},{"orgOrder":0,"company":"Sirnaomics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"STP705","moa":"COX-2","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Sirnaomics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Sirnaomics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Sirnaomics \/ Not Applicable"},{"orgOrder":0,"company":"Endevica Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"TCMCB07","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Endevica Bio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Endevica Bio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Endevica Bio \/ Not Applicable"},{"orgOrder":0,"company":"Amgen Inc","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2022","type":"Not Applicable","leadProduct":"AMG 133","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Amgen Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Amgen Inc \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Amgen Inc \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"ZP8396","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Viking Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"VK2735","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Viking Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Viking Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Viking Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OrsoBio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TLC-6740","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"OrsoBio","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"OrsoBio \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"OrsoBio \/ Not Applicable"},{"orgOrder":0,"company":"MindRank","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"MDR-001","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"MindRank","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"MindRank \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"MindRank \/ Not Applicable"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"ZP8396","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Zhejiang Doer Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2023","type":"Not Applicable","leadProduct":"DR10624","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zhejiang Doer Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Zhejiang Doer Biologics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zhejiang Doer Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"RDX-002","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Eccogene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Licensing Agreement","leadProduct":"ECC5004","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Eccogene","amount2":2.0099999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":2.0099999999999998,"dosageForm":"Tablet","sponsorNew":"Eccogene \/ AstraZeneca","highestDevelopmentStatusID":"6","companyTruncated":"Eccogene \/ AstraZeneca"},{"orgOrder":0,"company":"Terns Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"TERN-601","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Terns Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Terns Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Terns Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Carmot Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Acquisition","leadProduct":"CT-388","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Carmot Therapeutics","amount2":3.1000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":3.1000000000000001,"dosageForm":"Injection","sponsorNew":"Carmot Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"6","companyTruncated":"Carmot Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Keros Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"KER-065","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Keros Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Keros Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Keros Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Scholar Rock","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Apitegromab","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Scholar Rock","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Scholar Rock \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Scholar Rock \/ Not Applicable"},{"orgOrder":0,"company":"Gubra","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"GUB014295","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Gubra","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Gubra \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Gubra \/ Not Applicable"},{"orgOrder":0,"company":"Rhythm Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Undisclosed","year":"2024","type":"Not Applicable","leadProduct":"RM-718","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Rhythm Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Rhythm Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Rhythm Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"CIN-110","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"CinRx Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Veru","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Enobosarm","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Veru","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Veru \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Veru \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Amycretin","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Oxyntomodulin Analog","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"NeuroBo Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Response Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"RDX-002","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Response Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Response Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Response Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Metsera","sponsor":"ARCH Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Metsera","amount2":0.28999999999999998,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.28999999999999998,"dosageForm":"Injection","sponsorNew":"Metsera \/ ARCH Venture Partners","highestDevelopmentStatusID":"6","companyTruncated":"Metsera \/ ARCH Venture Partners"},{"orgOrder":0,"company":"Palatin Technologies","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Bremelanotide Acetate","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Palatin Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"Injection","sponsorNew":"Palatin Technologies \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Palatin Technologies \/ Not Applicable"},{"orgOrder":0,"company":"Novo Nordisk","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"NNC6022-0001","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Novo Nordisk","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Novo Nordisk \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Novo Nordisk \/ Not Applicable"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"DA-1726","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"NeuroBo Pharmaceuticals","sponsor":"H.C. Wainwright & Co","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Private Placement","leadProduct":"DA-1726","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"NeuroBo Pharmaceuticals","amount2":0.070000000000000007,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.070000000000000007,"dosageForm":"","sponsorNew":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co","highestDevelopmentStatusID":"6","companyTruncated":"NeuroBo Pharmaceuticals \/ H.C. Wainwright & Co"},{"orgOrder":0,"company":"Zealand Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"Petrelintide","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Zealand Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0,"dosageForm":"","sponsorNew":"Zealand Pharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Zealand Pharma \/ Not Applicable"},{"orgOrder":0,"company":"Biophytis","sponsor":"Atlas","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"20-Hydroxyecdysone","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"Biophytis","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.02,"dosageForm":"","sponsorNew":"Biophytis \/ Atlas","highestDevelopmentStatusID":"6","companyTruncated":"Biophytis \/ Atlas"},{"orgOrder":0,"company":"CinRx Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Nutrition and Weight Loss","country":"","productType":"Small molecule","year":"2024","type":"Financing","leadProduct":"CIN-109","moa":"","graph1":"Nutrition and Weight Loss","graph2":"Phase I","graph3":"CinRx Pharma","amount2":0.17999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Nutrition & Weight Loss","amount2New":0.17999999999999999,"dosageForm":"","sponsorNew":"CinRx Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"CinRx Pharma \/ Undisclosed"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Lilly will receive worldwide rights to develop and commercialize Dual Amylin Calcitonin Receptor Agonists (DACRA), a new class of potential treatments for obesity and related disorders.

                          Brand Name : LY3541105

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          October 10, 2024

                          Lead Product(s) : LY3541105

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Eli Lilly

                          Deal Size : $1,400.0 million

                          Deal Type : Expanded Collaboration

                          blank

                          02

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : The collaboration aims to ensure supply of Metsera’s portfolio of novel injectable and oral development programs, including MET-097, a GLP-1 receptor agonists and amylin receptor agonists.

                          Brand Name : MET-097

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          October 01, 2024

                          Lead Product(s) : MET-097

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Metsera

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : DA-1726 is a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity.

                          Brand Name : DA-1726

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 30, 2024

                          Lead Product(s) : Oxyntomodulin Analog

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : NPM115 (exenatide) implant i is being evaluated in the early-stage clinical trial studies for the treatment of obesity and Type 2 diabetes.

                          Brand Name : NPM115

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 26, 2024

                          Lead Product(s) : Exenatide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : ASC30 is an investigational small-molecule agonist biased toward GLP-1R. It is being evaluated as a once-daily oral tablet for the treatment of obesity.

                          Brand Name : ASC30

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 17, 2024

                          Lead Product(s) : ASC30

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : CT-996 is an investigational, once-daily, oral small molecule GLP-1 receptor agonist being developed for the treatment of both type 2 diabetes and obesity.

                          Brand Name : CT-996

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 11, 2024

                          Lead Product(s) : CT-996

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : F. Hoffmann-La Roche

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : IMM01-STEM, a secretome product derived from partially differentiated pluripotent stem cells that contains regenerative molecules, being investigated for sarcopenic obesity.

                          Brand Name : IMM01-STEM

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : IMM01-STEM

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          08

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : NN9487 (amycretin) is a novel oral, unimolecular co-agonist of both GLP-1 and amylin receptors that successfully completed phase 1 trial in Japanese Participants with Obesity

                          Brand Name : NN9487

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : Amycretin

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          09

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Saxenda is a GLP-1 receptor agonist indicated as an adjunct to a reduced-calorie diet and increased physical activity being investigated for chronic weight management in 6-12 years old patients.

                          Brand Name : Saxenda

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          September 10, 2024

                          Lead Product(s) : Liraglutide

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          10

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : TERN-601 is an oral, small-molecule glucagon-like peptide-1 receptor agonist product candidate, which is being evaluated for the treatment of obesity.

                          Brand Name : TERN-601

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          September 09, 2024

                          Lead Product(s) : TERN-601

                          Therapeutic Area : Nutrition and Weight Loss

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank